ASX-listed Kiwi biotechnology company Volpara Health Technologies has recommended shareholders accept an offer to acquire all its shares, in a deal that values the company at close to A$300 million.
The Wellington-based company, which has a core mission for the early detection of breast cancer, said
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
